Key Takeaways
- • Ayble Health closed a $16 million oversubscribed Series A funding round led by Neon, bringing total capital raised to over $27 million and establishing the company as a well-capitalized player in virtual gastroenterology care.
- • The round attracted participation from seven institutional investors including Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx, and Accomplice, plus strategic individual investors, signaling broad institutional confidence in the AI-enabled virtual GI clinic model.
- • Ayble Health positions itself as the nation's leading AI-enabled virtual multidisciplinary GI clinic, targeting a healthcare segment where virtual care adoption and gastroenterology demand continue to expand.
- • The oversubscribed nature of the round indicates strong investor demand and validates Ayble's clinical technology approach and market opportunity in specialized virtual healthcare.
Summary
Ayble Health announced the completion of a $16 million Series A funding round on September 17, 2026, with oversubscription from investors, positioning the Boston-based company as a funded player in the virtual gastroenterology market. The round was led by Neon and included participation from a diverse investor syndicate spanning venture capital firms (Upfront Ventures, M13, Accomplice), healthcare-focused venture investors (Unum Ventures, Cleveland Clinic Ventures, DigiTx), and strategic individual investors.
With this Series A close, Ayble Health has now raised over $27 million in total capital, reflecting sustained investor conviction in the company's AI-enabled virtual multidisciplinary gastroenterology platform. The round's oversubscription—where demand exceeded available investment allocation—suggests strong market appetite for Ayble's approach to specializing virtual care in gastrointestinal health, a field where both patient demand and clinician adoption of remote care models have accelerated.
The participation of Cleveland Clinic Ventures, a corporate venture arm of one of the nation's largest health systems, underscores potential strategic and clinical validation. The diversity of the investor base, spanning pure-play venture firms and healthcare-focused investors, indicates confidence in both the company's commercial execution and its clinical differentiation through AI integration.
With this Series A close, Ayble Health has now raised over $27 million in total capital, reflecting sustained investor conviction in the company's AI-enabled virtual multidisciplinary gastroenterology platform. The round's oversubscription—where demand exceeded available investment allocation—suggests strong market appetite for Ayble's approach to specializing virtual care in gastrointestinal health, a field where both patient demand and clinician adoption of remote care models have accelerated.
The participation of Cleveland Clinic Ventures, a corporate venture arm of one of the nation's largest health systems, underscores potential strategic and clinical validation. The diversity of the investor base, spanning pure-play venture firms and healthcare-focused investors, indicates confidence in both the company's commercial execution and its clinical differentiation through AI integration.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.